Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis

Thrombosis and Haemostasis

Volumn 90, Issue 4, 2003, Pages 710-716

  Rezaee, Farhard ^a   Gijbels, Marion ^b   Offerman, Erik ^a   Verheijen, Jan ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Collagen; Fibrinolysis; SMC; Transgenic mice

Indexed keywords

APOLIPOPROTEIN E3; BLOOD CLOTTING FACTOR 5 LEIDEN; CHOLESTEROL; COLLAGEN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CROSS BREEDING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; GENE DELETION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGENY; TRANSGENIC MOUSE;

EID: 0142092578     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-03-0160     Document Type: Article

References (62)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
2. Ross R. Atherosclerosis - An inflammatory disease. N Eng J Med 1999; 116: 115-26.
3. Davies MJ, et al. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Eng J Med 1984; 310: 1137-40.
4. Ross R, et al. The pathogenesis of atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven Publishers 1996; 441-60.
5. Dan K, et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
6. Saskela O, et al. Cell-associated plasminogen activation: Regulation and physiological functions. Ann Rev Cell Biol 1983; 4: 93-126.
7. Odekon LE, et al. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 1994; 158: 398-407.
8. Leeuwen RTJ. Extracellular proteolysis and the migration vascular smooth muscle cell. Fibrinolysis 1996; 10 (2): 59-74.
9. Carmeliet P, et al. Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis 1996; 26 (4): 132-53.
10. Carmeliet P, et al. Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998; 9: 255-85.
11. Amento EP, et al. Cytokines and growth factors positively and negatively regulates interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1991; 1: 1223-30.
12. Grainger DJ, et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-2.
13. Lawrence R, et al. Transforming growth factor beta 1 stimulates type V collagen expression in bovin vascular smooth cells. J Biol Cell 1994; 269: 9603-9.
14. Yamamoto K, et al. Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model. Circulation 2000; 102: 1308-14.
15. Hamsten A, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
16. Thogersen AM, et al. Plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1995; 322: 635-41.
17. Juhan-Vague I, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT study group. Circulation 1996; 94: 2057-63.
18. Held C, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with Verapamil or Metoprobol. Circulation 1997; 95: 2380-6.
19. Francis RB Jr, et al. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-80.
20. Olofsson BO, et al. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
21. Cortellaro M., et al. Increased fibrin turnover and high PAI-1 activity as predictor of ischemic events in atherosclerotic patients: A case control study: The PLAT group. Arterioscler Thromb Vasc Biol 1993; 13: 1412-7.
22. Lawn RM, et al. Atherosclerosis in transgenic mice expressing human apolipoprotein (a). Nature 1992; 360: 670-2.
23. Thompson SG, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
24. Ridker PM, et al. PAI-1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
25. Lowe GDO, et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 1998; 79: 129-33.
26. Ridker PM, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
27. Ridker PM, et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
28. Van De Loo JCW, et al. Hemostatic factors and the risk of myocardial infarction. N Eng J Med 1995; 332: 389-90.
29. Jansson JH, et al. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7-year follow-up. Circulation 1993; 88: 2030-4.
30. Nicole O, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7(1): 59-64.
31. Margaglione M, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler. Thromb Vasc Biol 1994; 14: 1741-5.
32. Schneiderman J, et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 1995; 96: 639-45.
33. Lupu F, et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
34. Stein MB, et al. Over-expression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999; 145: 173-80.
35. Carmeliet P, et al. Urokinase-generated plasmin activates matrix metalloproteinase during aneurysm formation. Nat Genet 1997; 17: 439-44.
36. Van Vlijmene BJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994; 93: 1403-10.
37. Van Vlijmen BJ, et al. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidaemic apolipoprotein E3-Leiden transgenic mice. J Lipid Res 1998; 39: 1181-8.
38. Zhao SP, et al. Lipoproteins in familial dysbetalipoproteinemia. Variation of serum cholesterol level associated with VLDL concentration. Arterioscler Thromb 1993; 13: 316-23.
39. Groot PH, et al. Quantitative assessment of aortic atherosclerosis in APOE3-Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 1996; 16: 926-33.
40. Leppanen P, et al. Characterization of atherosclerotic lesions in apoE3-Leiden transgenic mice. Atherosclerosis 1998; 136: 147-52.
41. Gijbels MJ, et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice. Atherosclerosis 1999; 143: 15-25.
42. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990; 31: 859-69.
43. Carmeliet P, et al. Plasminogen activator inhibitor-1 gene-deficient mice. Generation by homologous recombination and characterization. J. Clin Invest 1993; 92(6): 2746-55.
44. Carmeliet P, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368 (6470): 419-24.
45. Van Den Maagdenburg AMJM, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993; 268: 10540-5.
46. Paigen B, et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68(3): 231-40.
47. Rezaee F, et al. Overexpression of fibrinogen in ApoE*3-Leiden transgenic mice does not influence the progression of diet-induced atherosclerosis. Thromb Haemost 2002; 88 (2): 329-34.
48. Bradbury P, et al. Connective tissues and stains: In: Theory and Practice of Histological Techniques Bancroft. JD, Stevens A, editors. Churchill Livingstone, Medical Devision, London. Fourth edition 1996; 113-38.
49. Herbert JM, et al. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Cell 1994; 269: 3076-80.
50. Korner G, et al. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators. J Cell Physiol 1994; 154: 456-65.
51. Clowes AW, et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
52. Lutgens E, et al. Gas6 -/- / apoE -/- mice develop a collagen-rich, disorganized plaque phenotype, prone to intra- plaque bleeding. J Submicrosc Cytol Pathol 2000; 32 (3): C140,476.
53. Carmeliet P. Molecular analysis of vascular disorders. J Submicrosc Cytol Pathol 2000; 32 (3): S033,335.
54. Sjöland H, et al. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2000; 20: 846-52.
55. Xiao Q, et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A. 1997; 94(19): 10335-40.
56. Eitzman DT, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery Blood 2000; 96 (13): 4212-5.
57. Schäfer K, et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation 2002; 106(14): 1847-52.
58. Heymans S, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5(10): 1135-42.
59. Lijnen HR, et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18(7): 1035-45.
60. Matsuno H, et al. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81(4): 601-4.
61. Reilly JM. Plasminogen activators in abdominal aortic aneurysmal disease. Ann N Y Academic Sci 1996; 18: 151-6.
62. Kwan HC, et al. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82(10): 1702-8.